Publication:
Multiple Sclerosis Severity Score (MSSS) Improves the Accuracy of Individualized Prediction in MS

dc.authorwosidEichau, Sara/Aaa-8145-2019
dc.authorwosidTürkoğlu, Recai/B-9336-2014
dc.authorwosidOnofrj, Marco/K-7710-2016
dc.authorwosidMaimone, Davide/Ooj-9671-2025
dc.authorwosidTerzi̇, Murat/Aaa-1284-2021
dc.authorwosidLugaresi, Alessandra/C-7743-2012
dc.authorwosidSoysal, Aysun/Aax-7696-2021
dc.contributor.authorKalincik, Tomas
dc.contributor.authorKister, Ilya
dc.contributor.authorBacon, Tamar E.
dc.contributor.authorMalpas, Charles B.
dc.contributor.authorSharmin, Sifat
dc.contributor.authorHorakova, Dana
dc.contributor.authorCutter, Gary
dc.contributor.authorIDPrat, Alexane/0000-0001-6188-0580
dc.contributor.authorIDKister, Ilya/0000-0003-3549-949X
dc.contributor.authorIDTurkoglu, Recai/0000-0001-9724-851X
dc.contributor.authorIDPatti, Francesco/0000-0002-6923-0846
dc.contributor.authorIDMalpas, Charles/0000-0003-0534-3718
dc.contributor.authorIDLugaresi, Alessana/0000-0003-2902-5589
dc.date.accessioned2025-12-11T01:38:28Z
dc.date.issued2022
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Kister, Ilya; Bacon, Tamar E.] NYU, Neurol, Sch Med, 240 East 38th St, New York, NY 10026 USA; [Kalincik, Tomas; Malpas, Charles B.; Sharmin, Sifat] Univ Melbourne, CORe, Dept Med, Melbourne, Vic, Australia; [Kalincik, Tomas; Malpas, Charles B.; Sharmin, Sifat] Royal Melbourne Hosp, Dept Neurol, MS Ctr, Melbourne, Vic, Australia; [Horakova, Dana; Kubala-Havrdova, Eva] Charles Univ Prague, Dept Neurol, Prague, Czech Republic; [Patti, Francesco] Univ Catania, GF Ingrassia Dept, Catania, Italy; [Izquierdo, Guillermo; Eichau, Sara] Hosp Univ Virgen Macarena, Seville, Spain; [Ozakbas, Serkan] Dokuz Eylul Univ, Izmir, Turkey; [Onofrj, Marco] Univ G DAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Lugaresi, Alessandra] IRCCS Ist Sci Neurol Bologna, Bologna, Italy; [Lugaresi, Alessandra] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy; [Prat, Alexandre; Girard, Marc; Duquette, Pierre] Univ Montreal, Montreal, PQ, Canada; [Prat, Alexandre; Girard, Marc; Duquette, Pierre] CHUM, Montreal, PQ, Canada; [Grammond, Pierre] CISSS Chaudire Appalache, Levis, PQ, Canada; [Sola, Patrizia; Ferraro, Diana] Azienda Osped Univ, Dept Neurosci, Neurol Unit, Modena, Italy; [Ferraro, Diana] Univ Modena & Reggio Emilia, Dept Neurosci Metab & Neurosci, Modena, Italy; [Alroughani, Raed] Amiri Hosp, Dept Med, Div Neurol, Sharq, Kuwait; [Terzi, Murat] 19 Mayis Univ, Med Fac, Samsun, Turkey; [Boz, Cavit] KTU Med Fac, Farabi Hosp, Trabzon, Turkey; [Grand'Maison, Francois] Neuro Rive Sud, Greenfield Pk, PQ, Canada; [Bergamaschi, Roberto] IRCCS Mondino Fdn, Pavia, Italy; [Gerlach, Oliver] Zuyderland Med Ctr, Dept Neurol, Sittard Geleen, Netherlands; [Gerlach, Oliver] Maastricht Univ, Med Ctr, Dept Neurol, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Sa, Maria J.] Hosp Sao Joao, Porto, Portugal; [Sa, Maria J.] Univ Fernando Pessoa, Porto, Portugal; [Kappos, Ludwig] Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci RC2NB, Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Univ Hosp Basel, MS Ctr, Dept Head Spine & Neuromed, Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Univ Hosp Basel, MS Ctr, Dept Clin Res, Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Univ Hosp Basel, MS Ctr, Dept Biomed, Basel, Switzerland; [Cartechini, Elisabetta] Azienda Sanit Unica Reg Marche AV3, UOC Neurol, Macerata, Italy; [Lechner-Scott, Jeannette] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [van Pesch, Vincent] UCLouvain, Clin Univ St Luc, Brussels, Belgium; [Shaygannejad, Vahid] Isfahan Univ Med Sci, Esfahan, Iran; [Granella, Franco] Univ Parma, Dept Med & Surg, Parma, Italy; [Spitaleri, Daniele] Azienda Osped Rilievo Nazl San Giuseppe Moscati A, Avellino, Italy; [Iuliano, Gerardo] Osped Riuniti Salerno, Salerno, Italy; [Maimone, Davide] Neurol Unit, Piazza S Maria di Gesu 5, Catania, Italy; [Prevost, Julie] CSSS St Jerome, St Jerome, PQ, Canada; [Soysal, Aysun] Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Istanbul, Turkey; [Turkoglu, Recai] Haydarpasa Numune Training & Res Hosp, Istanbul, Turkey; [Ampapa, Radek] Nemocnice Jihlava, Jihlava, Czech Republic; [Butzkueven, Helmut] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [Cutter, Gary] UAB Sch Publ Hlth, Dept Biostat, Birmingham, AL USAen_US
dc.descriptionPrat, Alexane/0000-0001-6188-0580; Kister, Ilya/0000-0003-3549-949X; Turkoglu, Recai/0000-0001-9724-851X; Patti, Francesco/0000-0002-6923-0846; Malpas, Charles/0000-0003-0534-3718; Lugaresi, Alessana/0000-0003-2902-5589; Kappos, Ludwig/0000-0003-4175-5509; Kalincik, Tomas/0000-0003-3778-1376;en_US
dc.description.abstractBackground: The MSBase prediction model of treatment response leverages multiple demographic and clinical characteristics to estimate hazards of relapses, confirmed disability accumulation (CDA), and confirmed disability improvement (CDI). The model did not include Multiple Sclerosis Severity Score (MSSS), a disease duration-adjusted ranked score of disability. Objective: To incorporate MSSS into the MSBase prediction model and compare model accuracy with and without MSSS. Methods: The associations between MSSS and relapse, CDA, and CDI were evaluated with marginal proportional hazards models adjusted for three principal components representative of patients' demographic and clinical characteristics. The model fit with and without MSSS was assessed with penalized r2 and Harrell C. Results: A total of 5866 MS patients were started on disease-modifying therapy during prospective follow-up (age 38.4 +/- 10.6 years; 72% female; disease duration 8.5 +/- 7.7 years). Including MSSS into the model improved the accuracy of individual prediction of relapses by 31%, of CDA by 23%, and of CDI by 24% (Harrell C) and increased the amount of variance explained for relapses by 49%, for CDI by 11%, and for CDA by 10% as compared with the original model. Conclusion: Addition of a single, readily available metric, MSSS, to the comprehensive MSBase prediction model considerably improved the individual accuracy of prognostics in MS.en_US
dc.description.sponsorshipGenentech; NHMRC [1140766, 1129189]; Biogen; Novartis; Merck; Roche; Sanofi Genzyme; National Health and Medical Research Council of Australia [1129189] Funding Source: NHMRCen_US
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by an unrestricted investigator-initiated grant from Genentech. MSBase would like to acknowledge financial contributions to support the MSBase Registry from Biogen, Novartis, Merck, Roche, and Sanofi Genzyme. Authors acknowledge funding from NHMRC (1140766, 1129189) to develop the original prediction model.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1177/13524585221084577
dc.identifier.endpage1761en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.issue11en_US
dc.identifier.pmid35373638
dc.identifier.scopusqualityQ1
dc.identifier.startpage1752en_US
dc.identifier.urihttps://doi.org/10.1177/13524585221084577
dc.identifier.urihttps://hdl.handle.net/20.500.12712/45091
dc.identifier.volume28en_US
dc.identifier.wosWOS:000777910400001
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectMultiple Sclerosis Severity Score (MSSS)en_US
dc.subjectRelapse Predictionen_US
dc.subjectPrognosticsen_US
dc.titleMultiple Sclerosis Severity Score (MSSS) Improves the Accuracy of Individualized Prediction in MSen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files